11X Stock Market Accelerator Summit

Eric Fry reveals how an A.I.-based secret could make you up to 11 times RICHER on the same stocks you’re investing in now… without using options, leverage, or anything risky.

Wed, September 27 at 8:00PM ET

Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results


  • Athira Pharma (ATHA) stock is diving today on poor clinical trial data for fosgonimeton.
  • Fosgonimeton is a drug designed by the company to treat Alzheimer’s disease.
  • Athira’s Phase 2 clinical trial missed its primary endpoint.
Packs of blue and pink pills are piled on top of each other representing ATHA Stock.

Source: Shutterstock

Athira Pharma (NASDAQ:ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton.

Fosgonimeton is a treatment for Alzheimer’s disease currently being developed by the company. The clinical trial saw Athira Pharma testing the effectiveness of the drug in 77 patients suffering from “mild-to-moderate” Alzheimer’s disease.

Unfortunately for ATHA stock, the clinical trial was unable to meet its primary endpoint. That means it was unable to cause a statistically significant change in Event-Related-Potential (ERP) P300 Latency for those suffering from Alzheimer’s.

The fact the trial also failed to meet secondary endpoints adds salt to the wound today. These endpoints included significant cognitive, “global clinical” and functional changes when compared to a placebo.

Athira Pharma President and CEO Mark Litton isn’t giving up on fosgonimeton just yet, however:

“We are in the fortuitous situation that we have a much larger trial ongoing with more than 200 patients completing at least 20 weeks of treatment providing us with an opportunity to obtain more insights in an expedited manner. Our strong cash position allows us to continue to progress fosgonimeton development.”

ATHA stock is experiencing heavy trading today alongside the recent clinical trial data. This has some 10 million shares on the move as of this writing. That’s well above its daily average trading volume of about 294,000 shares.

ATHA stock is down 67% as of Wednesday morning.

There’s more stock market news for traders to dive into below!

We’ve got all the hottest stock news for Wednesday! That includes what’s happening with shares of Winnebago Industries (NYSE:WGO), Precision BioScience (NASDAQ:DTIL) and Revlon (NYSE:REV) stock today. You can read up on these matters at the following links!

More Wednesday Stock Market News

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Article printed from InvestorPlace Media, https://investorplace.com/2022/06/athira-pharma-atha-stock-plunges-65-on-disappointing-drug-trial-results/.

©2023 InvestorPlace Media, LLC